Extended Duration of Adjuvant Temozolomide in Glioblastoma Multiforme - A Review of Trials

被引：0
|
作者：
Pruthi, Deep Shankar [1 ]
Nagpal, Puneet [1 ]
Pandey, Manish [1 ]
机构：
[1] Act Canc Hosp, Dept Radiat Oncol, A-4, New Delhi, India
来源：
EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY | 2021年 / 5卷 / 03期
关键词：
Adjuvant; Glioblastoma Multiforme; Extended duration; Temozolomide; NEWLY-DIAGNOSED GLIOBLASTOMA; RANDOMIZED PHASE-III; PROLONGED TEMOZOLOMIDE; OPEN-LABEL; RADIOTHERAPY; CONCOMITANT; SURVIVAL; THERAPY;
D O I：
10.14744/ejmo.2021.20733
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Surgical resection followed by concurrent radiation therapy and temozolomide (TMZ) chemotherapy then adjuvant TMZ is the current standard treatment for glioblastoma multiforme (GBM). There is a lot of controversy regarding the duration of adjuvant TMZ. The standard guidelines recommend 6 months of adjuvant treatment, however in clinical practice in a lot of centers around the world, TMZ therapy is continued beyond 6 months duration. In this review article we will discuss both favorable and unfavorable trials regarding extended TMZ therapy and try to analyze in whom extended TMZ therapy is beneficial and whether or not it should be offered.
引用
收藏
页码：217 / 221
页数：5
相关论文
共 50 条
  • [11] The duration of adjuvant temozolomide in patients with glioblastoma and the law of diminishing returns
    Grossman, Stuart A.
    NEURO-ONCOLOGY, 2020, 22 (12) : 1721 - 1722
  • [12] Temozolomide resistance in glioblastoma multiforme
    Lee, Sang Y.
    GENES & DISEASES, 2016, 3 (03) : 198 - 210
  • [13] Glioblastoma multiforme in the era of temozolomide
    Altaha, Ramin
    Anis, Amir
    Almubarak, Mohammed
    NEURO-ONCOLOGY, 2007, 9 (04) : 520 - 520
  • [14] Temozolomide in glioblastoma multiforme of the elderly
    Brandes, AA
    Vastola, F
    Basso, U
    Pasetto, LM
    Ermani, M
    Berti, F
    Rotilio, A
    Amistà, P
    Scienza, R
    Monfardini, S
    TUMORI, 2002, 88 (01) : S69 - S70
  • [15] Extended adjuvant temozolomide improves survival in a glioblastoma mouse model
    Wang, Hanxiao
    Al-Holou, Wajd
    Heist, Kevin
    Galban, Craig J.
    deCarvalho, Ana C.
    Mikkelsen, Tom
    Ross, Brian D.
    Rehemtulla, Alnawaz
    CANCER RESEARCH, 2014, 74 (19)
  • [16] Extended adjuvant temozolomide in newly diagnosed glioblastoma: the more, the better?
    Zhao, Binghao
    Ma, Wenbin
    NEURO-ONCOLOGY, 2021, 23 (09) : 1614 - 1615
  • [17] Improved median survival for glioblastoma multiforme following introduction of adjuvant temozolomide chemotherapy
    Back, Michael F.
    Ang, Emily L. L.
    Ng, Wai-Hoe
    See, Siew-Ju
    Lim, C. C. Tchoyoson
    Chan, S. P.
    Yeo, Tseng-Tsai
    ANNALS ACADEMY OF MEDICINE SINGAPORE, 2007, 36 (05) : 338 - 342
  • [18] Radiotherapy with concomitant and adjuvant temozolomide in glioblastoma multiforme patients: Compliance analysis.
    Cartei, F.
    Carau, B.
    Ursino, S.
    Api, P.
    Fiorica, F.
    Cerruti, S.
    Cavallo, M.
    Padovani, R.
    RADIOTHERAPY AND ONCOLOGY, 2006, 81 : S296 - S296
  • [19] Concomitant chemoradiotherapy followed by adjuvant temozolomide improves survival in glioblastoma multiforme.
    Abrey L.E.
    Current Neurology and Neuroscience Reports, 2005, 5 (3) : 167 - 168
  • [20] Temozolomide and Radiotherapy for Newly Diagnosed Glioblastoma Multiforme: A Systematic Review
    Yang, Li-Juan
    Zhou, Chang-Fu
    Lin, Zhi-Xiong
    CANCER INVESTIGATION, 2014, 32 (02) : 31 - 36
12345